Validating indicators of CNS disorders in a swine model of neurological disease
AuthorSwier, Vicki J
White, Katherine A
Meyerholz, David K
Sieren, Jessica C
Quelle, Dawn E
Weimer, Jill M
AffiliationUniv Arizona, Coll Med, Dept Pharmacol
Univ Arizona, Coll Med, Grad Interdisciplinary Program Neurosci
MetadataShow full item record
PublisherPUBLIC LIBRARY SCIENCE
CitationSwier, V. J., White, K. A., Meyerholz, D. K., Chefdeville, A., Khanna, R., Sieren, J. C., ... & Weimer, J. M. (2020). Validating indicators of CNS disorders in a swine model of neurological disease. PloS one, 15(2), e0228222.
Rights© 2020 Swier et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at email@example.com.
AbstractGenetically modified swine disease models are becoming increasingly important for studying molecular, physiological and pathological characteristics of human disorders. Given the limited history of these model systems, there remains a great need for proven molecular reagents in swine tissue. Here, to provide a resource for neurological models of disease, we validated antibodies by immunohistochemistry for use in examining central nervous system (CNS) markers in a recently developed miniswine model of neurofibromatosis type 1 (NF1). NF1 is an autosomal dominant tumor predisposition disorder stemming from mutations in NF1, a gene that encodes the Ras-GTPase activating protein neurofibromin. Patients classically present with benign neurofibromas throughout their bodies and can also present with neurological associated symptoms such as chronic pain, cognitive impairment, and behavioral abnormalities. As validated antibodies for immunohistochemistry applications are particularly difficult to find for swine models of neurological disease, we present immunostaining validation of antibodies implicated in glial inflammation (CD68), oligodendrocyte development (NG2, O4 and Olig2), and neuron differentiation and neurotransmission (doublecortin, GAD67, and tyrosine hydroxylase) by examining cellular localization and brain region specificity. Additionally, we confirm the utility of anti-GFAP, anti-Iba1, and anti-MBP antibodies, previously validated in swine, by testing their immunoreactivity across multiple brain regions in mutant NF1 samples. These immunostaining protocols for CNS markers provide a useful resource to the scientific community, furthering the utility of genetically modified miniswine for translational and clinical applications.
NoteOpen access journal
VersionFinal published version
Except where otherwise noted, this item's license is described as © 2020 Swier et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
- A porcine model of neurofibromatosis type 1 that mimics the human disease.
- Authors: White KA, Swier VJ, Cain JT, Kohlmeyer JL, Meyerholz DK, Tanas MR, Uthoff J, Hammond E, Li H, Rohret FA, Goeken A, Chan CH, Leidinger MR, Umesalma S, Wallace MR, Dodd RD, Panzer K, Tang AH, Darbro BW, Moutal A, Cai S, Li W, Bellampalli SS, Khanna R, Rogers CS, Sieren JC, Quelle DE, Weimer JM
- Issue date: 2018 Jun 21
- Aberrant growth and differentiation of oligodendrocyte progenitors in neurofibromatosis type 1 mutants.
- Authors: Bennett MR, Rizvi TA, Karyala S, McKinnon RD, Ratner N
- Issue date: 2003 Aug 6
- Olig2-expressing progenitor cells preferentially differentiate into oligodendrocytes in cuprizone-induced demyelinated lesions.
- Authors: Islam MS, Tatsumi K, Okuda H, Shiosaka S, Wanaka A
- Issue date: 2009 Mar-Apr
- Mice with GFAP-targeted loss of neurofibromin demonstrate increased axonal MET expression with aging.
- Authors: Su W, Xing R, Guha A, Gutmann DH, Sherman LS
- Issue date: 2007 May
- New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors.
- Authors: Williams KB, Largaespada DA
- Issue date: 2020 Apr 28